DNA virus

Global CDC7 Kinase Inhibitors Clinical Trials & Market Insight Report 2024 Featuring Carna Biosciences, Chia Tai Tianqing Pharma, Eli Lilly, Memorial Sloan-Kettering Cancer Center, and Schrodinger - ResearchAndMarkets.com

Retrieved on: 
Thursday, January 11, 2024
Health, Oncology, Clinical Trials, Other Health, DNA virus, Cell division, Patient, Mitosis, Indication, DNA replication, Research, Viral, Radiation, DNA, S phase, DNA repair, DBF4, Cancer, Cell proliferation, CDC7, Cell death, Virus, Inflammation, VP3

The "Global CDC7 Kinase Inhibitors Clinical Trials & Market Opportunity Insight 2024" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global CDC7 Kinase Inhibitors Clinical Trials & Market Opportunity Insight 2024" report has been added to ResearchAndMarkets.com's offering.
  • The uncontrolled proliferation of cancer cells often involves dysregulation of DNA replication, and CDC7 kinase is often overexpressed in various cancer types.
  • In contrast, CDC7 kinase inhibitors focus on disrupting DNA replication process, offering a more specific and potentially less toxic approach.
  • Global CDC7 Kinase Inhibitors Clinical Trials & Market Opportunity Insight 2024 Report Highlights:
    Global CDC7 Kinase Inhibitors Clinical Pipeline By Company, Indication & Phase

DGAP-News: Monkeypox Is Popping Up In Places It Shouldn’t But NanoViricides Says It May Have A Solution

Retrieved on: 
Wednesday, August 10, 2022
Survival, Poxviridae, Research, Molluscum contagiosum, Fever, Patient, Family, Hepatitis C, Influenza, Hepatitis B virus, US, Monkeypox virus, Animal, Degenerative disease, Smallpox, Dengue fever, Travel, Technology, Fear, Kidney, DNA, Safety, EKC, Ulcer, DNA virus, Remdesivir, Monkeypox, Smallpox vaccine, Virus, Simplex, HBV, Pox, SIGA Technologies, US FDA, Rash, COVID-19, Bioterrorism, Drug development, Vaccination, Disease, HIV, HCV, Time, Keratitis, Advertising, FDA, Bird, VZV, NYSE, Population, Shingles, IND, Company, Lymph, Eye, NASDAQ, Human, Consultant, Gilead, Pharmaceutical industry, Vaccine, Rabies, West Nile virus, Central Africa

However, most of the monkeypox virus particles exit due to cell lysis, and are infectious even though not fully mature; this mode is not affected by TPOXX.

Key Points: 
  • However, most of the monkeypox virus particles exit due to cell lysis, and are infectious even though not fully mature; this mode is not affected by TPOXX.
  • It had shown effectiveness in monkeys to increase survival upon monkeypox virus infection.
  • Thus there is a clear and immediate need for rapid new drug development against monkeypox virus and potential variants.
  • During the smallpox eradication program in the late 1960s, the vaccine used to prevent smallpox also helped curb monkeypox infections.

Romidepsin for Injection Available from Fresenius Kabi

Retrieved on: 
Tuesday, July 12, 2022
Oncology, Medical Supplies, Health, Medical Devices, General Health, Pharmaceutical, Biotechnology, DNA virus, Infection, Nausea, Purging disorder, Thrombocytopenia, HDAC, T-cell lymphoma, Itch, INR, LLC, Birth, Neutropenia, Multimedia, Anemia, Potassium, History, CYP3A4, Risk, Hepatitis B, Patient, CEO, ECG, Fetus, Adult, Tumor lysis syndrome, Hepatitis, Cardiovascular disease, Leukopenia, CTCL, Injection, Pulmonary toxicity, Rifampicin, Toxicity, DNA, Fresenius (company), Lymphocytopenia, Fatigue, Warfarin, FDA, Magnesium, Constipation, Vomiting, Cancer, Prothrombin time, Female, Pharmaceutical industry, Vaccine, Medical imaging, Birth control, Romidepsin, Dysgeusia

Fresenius Kabi announced today the immediate availability in the United States of Romidepsin for Injection, the newest addition to the companys broad portfolio of injectable oncology medicines.

Key Points: 
  • Fresenius Kabi announced today the immediate availability in the United States of Romidepsin for Injection, the newest addition to the companys broad portfolio of injectable oncology medicines.
  • View the full release here: https://www.businesswire.com/news/home/20220712005418/en/
    Fresenius Kabi Romidepsin for Injection is the first approved generic equivalent for ISTODAX, providing clinicians and patients with a more affordable treatment option.
  • (Photo: Business Wire)
    Fresenius Kabi Romidepsin for Injection is the first approved generic equivalent for ISTODAX, providing clinicians and patients with a more affordable treatment option.
  • Fresenius Kabi Romidepsin is supplied as a kit including one 10 mg single-dose vial of Romidepsin and one 2.2 mL vial of diluent.

OncoMyx Presents New Data at SITC 2021 Demonstrating the Potential of a Multi-Armed Myxoma Virus as a Novel Oncolytic Immunotherapy for Solid Tumors and Heme Malignancies

Retrieved on: 
Friday, November 12, 2021
Pharmaceutical, Health, Oncology, Clinical Trials, IL-12, Immunity, SITC, Cancer, Lymphatic system, Therapy, Engineering, Potyvirus, CEO, MBA, Oncolytic virus, Immune system, Washington Convention Center, Society, Syngenic, Research, Myxoma virus, Rabbit, Human, AACR, Arizona, Twitter, Multiple myeloma, Conference, Genome, LinkedIn, Pox, Walter, Immunotherapy, Hare, DNA virus, DNA, Decorin, Patient, Myxoma, Arizona State University, Walter E. Washington Convention Center, Vaccine, Oncolytic Immunotherapy and Myxoma Virus, OncoMyx Therapeutics, ONCOLYTIC IMMUNOTHERAPY AND MYXOMA VIRUS, ONCOMYX THERAPEUTICS

The data demonstrate the potential of a multi-armed myxoma virotherapy for the treatment of solid tumors and heme malignancies.

Key Points: 
  • The data demonstrate the potential of a multi-armed myxoma virotherapy for the treatment of solid tumors and heme malignancies.
  • In addition to direct oncolytic effects on cancer cells, OncoMyxs multi-armed myxoma platform show additional anti-tumor activity through immune activation and tumor microenvironment modulation.
  • Furthermore, OncoMyx has previously established in a preclinical model of cancer that myxoma virus has anti-tumor efficacy following intravenous (IV) or intratumoral (IT) dosing (data presented at AACR 2021 ).
  • These data show the unmatched potential of our myxoma platform to be effective across a broad range of cancers, from hematological malignancies to solid tumors.

Karius receives New York State permit for its liquid biopsy test to detect infectious diseases

Retrieved on: 
Tuesday, August 17, 2021
Bloodstream infections, Twitter, Death, Cancer, Parasitology, Laboratory developed test, Infection, LDT, Parasitism, Bacteria, Fungus, Liquid biopsy, DNA, DNA virus, Health, CA, Immunodeficiency, Hospital, Multimedia, CAP, Mycology, Patient, CEO, Bacteriology, NYS, CLEP, Virology, Pharmaceutical industry, Vaccine

REDWOOD CITY, Calif., Aug. 17, 2021 /PRNewswire/ -- Karius, the world leader in liquid biopsy for infectious diseases, has received approval from the New York State Department of Health's Clinical Laboratory Evaluation Program (CLEP) for its Karius Test for pathogen detection.

Key Points: 
  • REDWOOD CITY, Calif., Aug. 17, 2021 /PRNewswire/ -- Karius, the world leader in liquid biopsy for infectious diseases, has received approval from the New York State Department of Health's Clinical Laboratory Evaluation Program (CLEP) for its Karius Test for pathogen detection.
  • The Karius Test is commercially available from a single CLIA-certified and CAP-accredited laboratory in Redwood City, CA, as a Laboratory Developed Test (LDT).
  • The decision by CLEP is a first-in-class approval of a clinical metagenomics test for the detection of infectious diseases, and will expand patient access to critical testing in New York.
  • The Karius Test is primarily used to detect specific causative pathogens in immunocompromised patients and other specific clinical syndromes.